Often used as an adjunctive therapy with other anticonvulsant (antiseizure) medication.
- TRADE NAME: Xcopri (SK Life Science)
- INDICATIONS: Partial-onset seizures in adults.
- CLASS: Anticonvulsant (see also antiepileptic (anti-seizure)), Antiepileptic (anti-seizure), GABA A receptor positive modulator
- HALF-LIFE: 50–60 hours
- FDA APPROVAL DATE: 11/21/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Clobazam, CYP2B6 substrates, CYP3A substrates, CYP2C19 substrates, Lamotrigine, Oral Contraceptives, Phenobarbital, Phenytoin - PREGNANCY: Based on animal data, may cause fetal harm. Women of reproductive potential concomitantly using oral contraceptives should use additional or alternative non-hormonal birth control.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 12/19/2025
